ALKS

Alkermes Plc. Q1 2025 Financial Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Alkermes Plc. is a global biopharmaceutical company focused on neuroscience, commercializing proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also generates revenue through manufacturing and royalty arrangements for third-party products, including long-acting INVEGA products and VUMERITY. In May 2024, the company completed the sale of its Athlone, Ireland facility to Novo Nordisk.

Key Financial Metrics

Note: The company prepaid and terminated its former term loans in December 2024, resulting in zero interest expense for Q1 2025.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $43.9 million (12.5%) year-over-year. This was driven primarily by a $54.8 million decrease in manufacturing and royalty revenues, largely due to the expiration of the royalty on U.S. net sales of INVEGA SUSTENNA in August 2024.
• Product Sales Growth: Net product sales increased by $11.0 million (4.7%) to $244.5 million. Growth was led by LYBALVI (+$13.0 million) and VIVITROL (+$3.3 million), offset by a decline in ARISTADA/ARISTADA INITIO sales (-$5.4 million).
• Expense Reduction: Total operating expenses decreased by $14.3 million. Selling, general, and administrative (SG&A) expenses fell by $8.0 million, and Cost of Goods Sold (COGS) decreased by $9.4 million, partly due to the sale of the Athlone facility and lower unit volumes for certain products.
• Profitability: Net income decreased by $14.4 million, primarily reflecting the significant drop in royalty revenue, despite lower operating expenses and a reduced income tax provision.

Outlook, Risks, and Management Commentary

• Guidance: Management expects royalty revenues from long-acting INVEGA products to remain lower in 2025 following the INVEGA SUSTENNA royalty expiration. The company anticipates existing cash and investments will be sufficient to finance operations for at least the next 12 months.
• R&D Focus: Significant resources are being allocated to ALKS 2680, a novel oral selective orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia. External R&D expenses for ALKS 2680 increased by $7.3 million year-over-year due to the initiation of Phase 2 clinical studies.
• Legal Proceedings:
  • INVEGA TRINZA: The U.S. Court of Appeals for the Federal Circuit affirmed a lower court decision in favor of Janssen regarding patent infringement claims against Mylan Labs in March 2025.
  • VUMERITY: A bench trial regarding patent infringement claims by Zydus is scheduled to begin on July 28, 2025.
  • Acorda Therapeutics: An appeal regarding an arbitration award is pending, with oral arguments scheduled for June 6, 2025.
• Market Risks: The company highlighted risks related to global trade policies, including new U.S. tariffs announced in April 2025, which could impact supply chain costs and market volatility.

Key Facts for Investor Verification

• Revenue Mix Shift: Verify the sustainability of product sales growth (LYBALVI, VIVITROL) against the structural decline in royalty revenue from INVEGA SUSTENNA.
• Cash Position: Confirm the liquidity runway given the $916.2 million in cash and investments and the absence of long-term debt.
• Patent Litigation Outcomes: Monitor the July 2025 VUMERITY trial and the June 2025 Acorda appeal, as outcomes could materially impact future royalty streams.
• Share Repurchases: Note that while a $400 million repurchase program was authorized in 2024, no shares were repurchased under this program in Q1 2025; $200 million remains authorized.
• Medicaid Rebates: Verify the impact of the $8.7 million reduction in VIVITROL Medicaid rebate reserves on future earnings estimates.